ASTRAZENECA PHARMA INDIA LTD. - Launch Of Tremelimumab (Imjudo)

We refer to our earlier communication dated June 1, 2023, intimating the receipt of Import and Market permission in Form CT-20 from Drugs Controller General of India for Tremelimumab (Imjudo) concentration for solution for infusion 20 mg/ml (25 mg/ml and 300 mg/15 ml presentations in single dose vials) administered through intravenous route. With regard to the same, we wish to further update that the Company will launch Trmelimumab (Imjudo) in October 2024 in India.